Farrow Jeffrey S — SEC insider filings
SEC reporting owner CIK 1405253. 25 insider filings on record with FilingPulse; latest filed 2026-10-15.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2021-02-03 to 2026-10-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 6 filings — 80,044 shares, $4,470,256 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 79.
- Largest priced transaction: sale of 31,441 shares @ $68.00 ($2,137,988) in Global Blood Therapeutics, Inc., filed 2022-09-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | See Remarks | 11 | — | 9 legs · 48,603 sh · $2,332,268 | 19 |
| Global Blood Therapeutics, Inc. (GBT) | Chief Financial Officer | 11 | — | 1 leg · 31,441 sh · $2,137,988 | 57 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | Director | 2 | — | — | 3 |
| LISATA THERAPEUTICS, INC. (LSTA) | Director | 1 | — | — | — |
Insider filings — Farrow Jeffrey S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-15 | 3 | LISATA THERAPEUTICS, INC. (LSTA) | Holdings only — no transactions reported | EDGAR |
| 2026-07-29 | 4 | ACHIEVE LIFE SCIENCES, INC. (ACHV) | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 16,700 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 27,881 · Sale (S): 14,396 @ $60.95 · Option exercise (M): 27,881 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | ACHIEVE LIFE SCIENCES, INC. (ACHV) | Grant/award (A): 47,250 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 2,111 @ $69.42 · Sale (S): 2,133 @ $68.71 · Sale (S): 2,186 @ $67 | EDGAR |
| 2026-03-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 13,042 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 27,881 · Sale (S): 13,608 @ $40.42 · Option exercise (M): 27,881 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 1,284 @ $46.29 · Sale (S): 1,254 @ $47.40 · Sale (S): 1,186 @ $50.11 | EDGAR |
| 2025-03-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 8,019 · Option exercise (M): 8,019 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 30,628 (derivative) @ $0 · Grant/award (A): 20,089 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 27,881 · Sale (S): 10,445 @ $27.47 · Option exercise (M): 27,881 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 47,500 (derivative) @ $0 · Grant/award (A): 32,079 (derivative) @ $0 | EDGAR |
| 2023-04-26 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 163,397 (derivative) @ $0 · Grant/award (A): 111,525 (derivative) @ $0 | EDGAR |
| 2022-10-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Disposition to issuer (D): 26,739 · Disposition to issuer (D): 3,125 (derivative) · Disposition to issuer (D): 9,060 (derivative) · Disposition to issuer (D): 13,814 (derivative) · Disposition to issuer (D): 15,460 (derivative) · Disposition to issuer (D): 26,454 (derivative) · +8 more | EDGAR |
| 2022-09-29 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 23,653 @ $16.40 · Option exercise (M): 23,653 (derivative) @ $0 | EDGAR |
| 2022-09-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 2,763 · Option exercise (M): 2,208 · Tax withholding (F): 1,885 @ $68.15 · Sale (S): 31,441 @ $68 · Option exercise (M): 2,763 (derivative) @ $0 · Option exercise (M): 2,208 (derivative) @ $0 | EDGAR |
| 2022-08-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 6,145 · Tax withholding (F): 2,126 @ $32.40 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 2,763 · Tax withholding (F): 1,315 @ $29.87 · Option exercise (M): 2,763 (derivative) @ $0 · Grant/award (A): 17,668 (derivative) @ $0 · Grant/award (A): 17,668 (derivative) @ $0 · Grant/award (A): 28,628 (derivative) @ $0 | EDGAR |
| 2022-02-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 9,020 · Tax withholding (F): 4,506 @ $29.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0 | EDGAR |
| 2021-09-24 | 4/A | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 9,020 · Tax withholding (F): 4,354 @ $27.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 2,762 · Tax withholding (F): 1,370 @ $29.85 · Option exercise (M): 2,762 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 9,020 · Tax withholding (F): 4,354 @ $27.33 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Grant/award (A): 38,739 (derivative) @ $0 · Grant/award (A): 22,102 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 12,083 · Tax withholding (F): 5,865 @ $49.49 · Option exercise (M): 3,063 (derivative) @ $0 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 · Option exercise (M): 3,020 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1405253 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs